Celgene (NASDAQ:CELG) received a $123.00 target price from equities research analysts at Credit Suisse Group in a research report issued on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target suggests a potential upside of 14.02% from the stock’s current price.
Several other brokerages also recently issued reports on CELG. BMO Capital Markets lifted their price objective on Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer restated a “buy” rating and set a $170.00 price objective on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research report on Monday, October 23rd. Cann restated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley upgraded Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $135.43.
Shares of Celgene (NASDAQ:CELG) opened at $107.88 on Friday. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The stock has a market cap of $84,940.00, a P/E ratio of 16.92, a PEG ratio of 0.84 and a beta of 1.77.
In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its position in Celgene by 4,290.5% during the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares during the period. BlackRock Inc. boosted its position in Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. purchased a new stake in Celgene during the 2nd quarter worth $271,605,000. Arrowstreet Capital Limited Partnership boosted its position in Celgene by 1,489.2% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after purchasing an additional 1,787,052 shares during the period. Finally, Vanguard Group Inc. boosted its position in Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares during the period. 79.84% of the stock is owned by institutional investors.
About Celgene
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
